Epigenetic prediction of response to anti-PD-1 treatment in non-small-cell lung cancer: a multicentre, retrospective analysis. Duruisseaux Michäel et al. The Lancet. Respiratory medicine 2018 6(10) 771-781

Main|Search|PHGKB




Last Posted: Jul 05, 2019

---

• Epigenetic prediction of response to anti-PD-1 treatment in non-small-cell lung cancer: a multicentre, retrospective analysis.
  Duruisseaux Michäel et al. The Lancet. Respiratory medicine 2018 6(10) 771-781
• Development of Cancer Immunotherapy
  NCI, June 2019
• Overall survival in patients with BRAF-mutant melanoma receiving encorafenib plus binimetinib versus vemurafenib or encorafenib (COLUMBUS): a multicentre, open-label, randomised, phase 3 trial.
  Dummer Reinhard et al. The Lancet. Oncology 2018 19(10) 1315-1327
• A Rapidly Emerging Field of Cancer Treatment
  B Ciupka, NFCR, June 2019
• Donor-specific circulating cell free DNA as a noninvasive biomarker of graft injury in heart transplantation.
  Macher Hada Celicia et al. Clinica chimica acta; international journal of clinical chemistry 2019 Jun
• IAPSO-AIRS: A novel improved machine learning-based system for wart disease treatment.
  Abdar Moloud et al. Journal of medical systems 2019 Jun 43(7) 220
• Safer CAR T-Cell Therapy
  J Abbasi, JAMA, June 11, 2019
• Clinical implications of genetic aberrations in metastatic prostate cancer.
  Reichert Zachery R et al. Current opinion in urology 2019 Jul 29(4) 319-325
• The road map of cancer precision medicine with the innovation of advanced cancer detection technology and personalized immunotherapy.
  Low Siew-Kee et al. Japanese journal of clinical oncology 2019 May
• New Drugs, New Side Effects: Complications of Cancer Immunotherapy 
  NCI, May 2019

more